User profiles for Jingyou Yu

Jingyou Yu

Guangzhou National Laboratory
Verified email at gzlab.ac.cn
Cited by 10320

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

J Yu, LH Tostanoski, L Peter, NB Mercado, K McMahan… - Science, 2020 - science.org
The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top …

[HTML][HTML] Correlates of protection against SARS-CoV-2 in rhesus macaques

K McMahan, J Yu, NB Mercado, C Loos, LH Tostanoski… - Nature, 2021 - nature.com
Recent studies have reported the protective efficacy of both natural 1 and vaccine-induced
2 , 3 , 4 , 5 , 6 – 7 immunity against challenge with severe acute respiratory syndrome …

[HTML][HTML] Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

…, R Zahn, F Wegmann, C Loos, A Chandrashekar, J Yu… - Nature, 2020 - nature.com
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
may be required to end the coronavirus disease 2019 (COVID-19) pandemic 1 , 2 , 3 , 4 …

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

…, NB Mercado, L Peter, LH Tostanoski, J Yu… - Science, 2020 - science.org
An understanding of protective immunity to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global …

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

…, AJ Iafrate, SB Calderwood, SA Lauer, J Yu… - Science …, 2020 - science.org
We measured plasma and/or serum antibody responses to the receptor-binding domain (RBD)
of the spike (S) protein of SARS-CoV-2 in 343 North American patients infected with …

[PDF][PDF] Distinct early serological signatures track with SARS-CoV-2 survival

…, C Loos, DJ McCulloch, KL Newman, C Wolf, J Yu… - Immunity, 2020 - cell.com
As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some
individuals recover from infection, whereas others rapidly progress and die. Although the …

[PDF][PDF] Approaches and challenges in SARS-CoV-2 vaccine development

G Dagotto, J Yu, DH Barouch - Cell host & microbe, 2020 - cell.com
The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this
global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than …

[HTML][HTML] Neutralization of the SARS-CoV-2 Omicron BA. 1 and BA. 2 variants

J Yu, AY Collier, M Rowe, F Mardas… - … England Journal of …, 2022 - Mass Medical Soc
Neutralization of Omicron BA.1 and BA.2 Variants Although two doses of BNT162b2 vaccine
produce immunity that wanes over time, the administration of a booster dose substantially …

[HTML][HTML] Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron

…, K McMahan, M Sciacca, H VanWyk, C Wu, J Yu… - Nature, 2022 - nature.com
The highly mutated SARS-CoV-2 Omicron (B.1.1.529) variant has been shown to evade a
substantial fraction of neutralizing antibody responses elicited by current vaccines that encode …

Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women

YC Ai-ris, K McMahan, J Yu, LH Tostanoski, R Aguayo… - Jama, 2021 - jamanetwork.com
Importance Pregnant women are at increased risk of morbidity and mortality from COVID-19
but have been excluded from the phase 3 COVID-19 vaccine trials. Data on vaccine safety …